Sponsors (3)
The bill opens Medicaid and federal programs to broader value‑based drug payment arrangements that could lower costs and improve outcomes but creates meaningful administrative burdens, fiscal risks, and access/equity concerns that may blunt or delay net public benefit.
State Medicaid programs and Medicaid beneficiaries: expanded authority to use value‑based drug pricing across inpatient and outpatient settings, creating opportunities to lower net Medicaid drug spending and link payment to outcomes.
Medicaid beneficiaries and patients with complex or chronic conditions: incentives for manufacturers to enter outcome‑based contracts that could improve clinical results and increase access to specialty or transformative therapies.
Federal programs, state agencies, manufacturers, and providers: clearer, faster regulatory pathways (statutory rulemaking/OIG timelines and required studies) that reduce uncertainty and speed adoption of value‑based arrangements.
Manufacturers and, indirectly, taxpayers and state Medicaid programs: changes in 'best price' and rebate treatment (including installment payment treatment) could create large upfront Medicaid rebate liabilities that discourage value‑based designs or shift costs elsewhere (e.g., higher list prices).
Manufacturers, HHS, States, and providers: expanded AMP/ reporting requirements, multi‑State coordination, and new data collection will increase administrative and compliance burdens and raise short‑term costs.
State governments and taxpayers: implementing value‑based arrangements and multi‑State billing/transfer systems may require legal, actuarial, IT, and administrative investments that could divert funds and create fiscal risk if savings do not materialize.
Based on analysis of 6 sections of legislative text.
Permits value-based purchasing for outpatient drugs by changing Medicaid/Medicare pricing and rebate rules, adding a State-focused antikickback exception, issuing State guidance, and mandating a GAO study.
Introduced May 7, 2025 by Markwayne Mullin · Last progress May 7, 2025
Allows and clarifies use of value-based purchasing (VBP) arrangements for outpatient drugs across Medicaid and Medicare by changing drug-pricing and rebate rules, creating a narrow antikickback exception for outcome-tied payments to States, requiring HHS guidance for State Medicaid use of VBPs (including multi-State payment coordination), and directing the GAO to study effects on access, costs, and program interactions. It requires HHS and the HHS Office of Inspector General to issue rules and guidance within 180 days and directs a GAO report by June 30, 2029. The law changes how manufacturers report "best price" and how Average Manufacturer Price (AMP) and Medicare Average Sales Price (ASP) are calculated when drugs are sold under VBP arrangements, adds a safe harbor to permit outcome-tied remuneration to States, and aims to enable broader State adoption of VBP models while studying impacts on patients, program spending, and pricing programs like 340B and Medicare Part B.